Bank of America initiated coverage on shares of Aegerion Pharmaceuticals (NASDAQ: AEGR) in a research report sent to investors on Tuesday morning. The firm issued a buy rating and a $39.00 price target on the stock.
“AEGR’s newly launched drug lomitapide (Juxtapid) is indicated for patients with very high LDL levels caused by a rare genetic disorder referred to as homozygous familial hypercholesteremia (HoFH). Our discussions with lipidologists indicated there is high awareness level and undermet need for treating this disorder. … Our near and intermediate-term sales estimates are ~75% above consensus but still conservative in our view vs. other recent ultra orphan drug launches, particularly if patient identification is less of a challenge.,” the firm’s analyst wrote.
AEGR has been the subject of a number of other recent research reports. Analysts at Lazard Capital Markets upgraded shares of Aegerion Pharmaceuticals from a neutral rating to a buy rating in a research note to investors on Monday, February 11th. Separately, analysts at Deutsche Bank raised their price target on shares of Aegerion Pharmaceuticals from $30.00 to $37.00 in a research note to investors on Monday, January 28th. They now have a buy rating on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Aegerion Pharmaceuticals from $30.00 to $35.00 in a research note to investors on Thursday, January 24th. They now have an outperform rating on the stock.
Aegerion Pharmaceuticals traded up 0.14% on Tuesday, hitting $36.17. Aegerion Pharmaceuticals has a 1-year low of $11.75 and a 1-year high of $37.10. The stock’s 50-day moving average is currently $28.72. The company’s market cap is $921.5 million.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
